您好,欢迎访问三七文档
当前位置:首页 > 临时分类 > 对比FDA和CFDA批准的抗癌药物列表
对比FDA和CFDA批准的抗癌药物列表。发现事实。下面的都是FDA批准的靶点药,而有中文名称的是CFDA允许在国内销售的。可以说,国内病人基本享受不到自从05年以来的绝大多数抗癌研究成果。为父亲大人学习相关知识。AgentTarget(s)FDA-approvedindication(s)CFDAapprovedAdo-trastuzumabemtansine(Kadcyla)HER2(ERBB2/neu)Breastcancer(HER2+)Afatinib(Gilotrif)EGFR(HER1/ERBB1),HER2(ERBB2/neu)Non-smallcelllungcancer(withEGFRexon19deletionsorexon21substitution(L858R)mutations)Aldesleukin(Proleukin)RenalcellcarcinomaMelanomaAlemtuzumab(Campath)CD52B-cellchroniclymphocyticleukemiaAxitinib(Inlyta)KIT,PDGFRβ,VEGFR1/2/3RenalcellcarcinomaBelimumab(Benlysta)BAFFLupuserythematosusBelinostat(Beleodaq)HDACPeripheralT-celllymphomaBevacizumab(Avastin)VEGFligandCervicalcancer贝伐珠单抗注射液ColorectalcancerFallopiantubecancerGlioblastomaNon-smallcelllungcancerOvariancancerPeritonealcancerRenalcellcarcinomaBortezomib(Velcade)ProteasomeMultiplemyeloma注射用硼替佐米[1]|2014-12-3011:28jasteeMantlecelllymphomaBosutinib(Bosulif)ABLChronicmyelogenousleukemia(Philadelphiachromosomepositive)Brentuximabvedotin(Adcetris)CD30HodgkinlymphomaAnaplasticlargecelllymphomaCabozantinib(Cometriq)FLT3,KIT,MET,RET,VEGFR2MedullarythyroidcancerCanakinumab(Ilaris)IL-1βJuvenileidiopathicarthritisCryopyrin-associatedperiodicsyndromesCarfilzomib(Kyprolis)ProteasomeMultiplemyelomaCeritinib(Zykadia)ALKNon-smallcelllungcancer(withALKfusion)Cetuximab(Erbitux)EGFR(HER1/ERBB1)Colorectalcancer(KRASwildtype)西妥昔单抗注射液SquamouscellcanceroftheheadandneckCrizotinib(Xalkori)ALK,METNon-smallcelllungcancer(withALKfusion)克唑替尼胶囊Dabrafenib(Tafinlar)BRAFMelanoma(withBRAFV600mutation)Dasatinib(Sprycel)ABLChronicmyelogenousleukemia(Philadelphiachromosomepositive)达沙替尼片Acutelymphoblasticleukemia(Philadelphiachromosomepositive)Denosumab(Xgeva)RANKLGiantcelltumoroftheboneErlotinib(Tarceva)EGFR(HER1/ERBB1)Non-smallcelllungcancer盐酸厄洛替尼片PancreaticcancerEverolimus(Afinitor)mTORPancreaticneuroendocrinetumor依维莫司片RenalcellcarcinomaNonresectablesubependymalgiantcellastrocytomaassociatedwithtuberoussclerosisBreastcancer(HR+,HER2-)Gefitinib(Iressa)EGFR(HER1/ERBB1)Non-smallcelllungcancerwithknownpriorbenefitfromgefitinib(limitedapproval)吉非替尼片Ibritumomabtiuxetan(Zevalin)CD20Non-Hodgkin'slymphomaIbrutinib(Imbruvica)BTKMantlecelllymphoma|2014-12-3011:29jasteeChroniclymphocyticleukemiaIdelalisib(Zydelig)PI3KδChroniclymphocyticleukemiaFollicularB-cellnon-HodgkinlymphomaSmalllymphocyticlymphomaImatinib(Gleevec)KIT,PDGFR,ABLGIstromaltumor(KIT+)DermatofibrosarcomaprotuberansMultiplehematologicmalignanciesincludingPhiladelphiachromosome-positiveALLandCMLIpilimumab(Yervoy)CTLA-4MelanomaLapatinib(Tykerb)HER2(ERBB2/neu),EGFR(HER1/ERBB1)Breastcancer(HER2+)Nilotinib(Tasigna)ABLChronicmyelogenousleukemia(Philadelphiachromosomepositive)尼洛替尼胶囊Obinutuzumab(Gazyva)CD20ChroniclymphocyticleukemiaOfatumumab(Arzerra,HuMax-CD20)CD20ChroniclymphocyticleukemiaPanitumumab(Vectibix)EGFR(HER1/ERBB1)Colorectalcancer(KRASwildtype)Pazopanib(Votrient)VEGFR,PDGFR,KITRenalcellcarcinomaPembrolizumab(Keytruda)PD-1MelanomaPertuzumab(Perjeta)HER2(ERBB2/neu)Breastcancer(HER2+)Ponatinib(Iclusig)ABL,FGFR1-3,FLT3,VEGFR2ChronicmyelogenousleukemiaAcutelymphoblasticleukemia(Philadelphiachromosomepositive)Ramucirumab(Cyramza)VEGFR2GastriccancerorGastroesophagealjunction(GEJ)adenocarcinomaRegorafenib(Stivarga)KIT,PDGFRβ,RAF,RET,VEGFR1/2/3ColorectalcancerGastrointestinalstromaltumorsRituximab(Rituxan,Mabthera)CD20Non-Hodgkin’slymphoma.利妥昔单抗注射液ChroniclymphocyticleukemiaRheumatoidarthritisGranulomatosiswithpolyangiitisRomidepsin(Istodax)HDACCutaneousT-celllymphomaPeripheralT-celllymphomaRuxolitinib(Jakafi)JAK1/2MyelofibrosisSiltuximab(Sylvant)IL-6MulticentricCastleman'sdiseaseSipuleucel-T(Provenge)ProstatecancerSorafenib(Nexavar)VEGFR,PDGFR,KIT,RAFHepatocellularcarcinoma甲苯磺酸索拉非尼片RenalcellcarcinomaThyroidcarcinomaTemsirolimus(Torisel)mTORRenalcellcarcinomaTocilizumab(Actemra)IL-6RRheumatoidarthritis托珠单抗注射液JuvenileidiopathicarthritisTofacitinib(Xeljanz)JAK3RheumatoidarthritisTositumomab(Bexxar)CD20Non-Hodgkin'slymphomaTrametinib(Mekinist)MEKMelanoma(withBRAFV600mutation)Trastuzumab(Herceptin)HER2(ERBB2/neu)Breastcancer(HER2+)注射用曲妥珠单抗(Gastriccancer(HER2+)Vandetanib(Caprelsa)EGFR(HER1/ERBB1),RET,VEGFR2MedullarythyroidcancerVemurafenib(Zelboraf)BRAFMelanoma(withBRAFV600mutation)Vismodegib(Erivedge)PTCH,SmoothenedBasalcellcarcinomaVorinostat(Zolinza)HDACCutaneousT-celllymphomaZiv-aflibercept(Zaltrap)PIGF,VEGFA/BColorectalcancer
本文标题:对比FDA和CFDA批准的抗癌药物列表
链接地址:https://www.777doc.com/doc-4370721 .html